CovidV1, Istex, Corpus, bibRecord, 000164

The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit

Identifieur interne : 000164 ( Istex/Corpus ); précédent : 000163; suivant : 000165

The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit

Source :

Journal of Antimicrobial Chemotherapy [ 0305-7453 ] ; 1986.

RBID : ISTEX:0077763261C42E983E3613F4E9CE41A21A08074A

Abstract

Intranasal sprays of interferons (IFNs) given one day before and for three days after virus challenge can protect human volunteers from infection with rhinoviruses, corona virus, and influenza. Longer dosage of IFN gives rise to nasal symptoms and signs such as bloodstained nasal discharge. More effective IFNs and regimes are therefore needed. IFNβ is active but the degree to which it will irritate the nose is unknown. Combining IFNs with synthetic antiviral drugs can produce synergistic increases in antiviral activity. It is suggested that these increases may be exploited in future experiments.

Url:

https://api.istex.fr/ark:/67375/HXZ-1543SRG0-R/fulltext.pdf

DOI: 10.1093/jac/18.Supplement_B.153

Links to Exploration step

ISTEX:0077763261C42E983E3613F4E9CE41A21A08074A

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit</title>
<author wicri:is="90%"><name sortKey="Tyrrell, D A J" sort="Tyrrell, D A J" uniqKey="Tyrrell D" first="D. A. J." last="Tyrrell">D. A. J. Tyrrell</name>
<affiliation><mods:affiliation>MRC Common Cold Unit, Harvard Hospital, Salisbury Wiltshire, England</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:0077763261C42E983E3613F4E9CE41A21A08074A</idno>
<date when="1986" year="1986">1986</date>
<idno type="doi">10.1093/jac/18.Supplement_B.153</idno>
<idno type="url">https://api.istex.fr/ark:/67375/HXZ-1543SRG0-R/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000164</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000164</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit</title>
<author wicri:is="90%"><name sortKey="Tyrrell, D A J" sort="Tyrrell, D A J" uniqKey="Tyrrell D" first="D. A. J." last="Tyrrell">D. A. J. Tyrrell</name>
<affiliation><mods:affiliation>MRC Common Cold Unit, Harvard Hospital, Salisbury Wiltshire, England</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Journal of Antimicrobial Chemotherapy</title>
<title level="j" type="abbrev">J Antimicrob Chemother</title>
<idno type="ISSN">0305-7453</idno>
<idno type="eISSN">1460-2091</idno>
<imprint><publisher>Oxford University Press</publisher>
<date when="1986-10">1986</date>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">Supplemet_B</biblScope>
<biblScope unit="page" from="153">153</biblScope>
<biblScope unit="page" to="156">156</biblScope>
</imprint>
<idno type="ISSN">0305-7453</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0305-7453</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Intranasal sprays of interferons (IFNs) given one day before and for three days after virus challenge can protect human volunteers from infection with rhinoviruses, corona virus, and influenza. Longer dosage of IFN gives rise to nasal symptoms and signs such as bloodstained nasal discharge. More effective IFNs and regimes are therefore needed. IFNβ is active but the degree to which it will irritate the nose is unknown. Combining IFNs with synthetic antiviral drugs can produce synergistic increases in antiviral activity. It is suggested that these increases may be exploited in future experiments.</div>
</front>
</TEI>
<istex><corpusName>oup</corpusName>
<keywords><teeft><json:string>interferon</json:string>
<json:string>ifns</json:string>
<json:string>antiviral</json:string>
<json:string>rhinovirus</json:string>
<json:string>tyrrell</json:string>
<json:string>phillpotts</json:string>
<json:string>intranasal interferon</json:string>
<json:string>rhinovirus infection</json:string>
<json:string>ifna</json:string>
<json:string>higgins</json:string>
<json:string>common cold unit</json:string>
<json:string>antiviral effect</json:string>
<json:string>intranasal</json:string>
<json:string>human volunteer</json:string>
<json:string>antiviral activity</json:string>
<json:string>antimicrobial chemotherapy</json:string>
<json:string>escherichia coli</json:string>
<json:string>unwanted effect</json:string>
</teeft>
</keywords>
<author><json:item><name>D. A. J. Tyrrell</name>
<affiliations><json:string>MRC Common Cold Unit, Harvard Hospital, Salisbury Wiltshire, England</json:string>
</affiliations>
</json:item>
</author>
<arkIstex>ark:/67375/HXZ-1543SRG0-R</arkIstex>
<language><json:string>unknown</json:string>
</language>
<originalGenre><json:string>research-article</json:string>
</originalGenre>
<abstract>Intranasal sprays of interferons (IFNs) given one day before and for three days after virus challenge can protect human volunteers from infection with rhinoviruses, corona virus, and influenza. Longer dosage of IFN gives rise to nasal symptoms and signs such as bloodstained nasal discharge. More effective IFNs and regimes are therefore needed. IFNβ is active but the degree to which it will irritate the nose is unknown. Combining IFNs with synthetic antiviral drugs can produce synergistic increases in antiviral activity. It is suggested that these increases may be exploited in future experiments.</abstract>
<qualityIndicators><score>3.093</score>
<pdfWordCount>1322</pdfWordCount>
<pdfCharCount>7867</pdfCharCount>
<pdfVersion>1.4</pdfVersion>
<pdfPageCount>4</pdfPageCount>
<pdfPageSize>486 x 720 pts</pdfPageSize>
<pdfWordsPerPage>331</pdfWordsPerPage>
<pdfText>true</pdfText>
<refBibsNative>false</refBibsNative>
<abstractWordCount>92</abstractWordCount>
<abstractCharCount>602</abstractCharCount>
<keywordCount>0</keywordCount>
</qualityIndicators>
<title>The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit</title>
<pmid><json:string>3025154</json:string>
</pmid>
<genre><json:string>research-article</json:string>
</genre>
<host><title>Journal of Antimicrobial Chemotherapy</title>
<language><json:string>unknown</json:string>
</language>
<issn><json:string>0305-7453</json:string>
</issn>
<eissn><json:string>1460-2091</json:string>
</eissn>
<publisherId><json:string>jac</json:string>
</publisherId>
<volume>18</volume>
<issue>Supplement-B</issue>
<pages><first>153</first>
<last>156</last>
</pages>
<genre><json:string>journal</json:string>
</genre>
</host>
<namedEntities><unitex><date><json:string>1986</json:string>
</date>
<geogName></geogName>
<orgName><json:string>Society for Antimicrobial Chemotherapy</json:string>
</orgName>
<orgName_funder></orgName_funder>
<orgName_provider></orgName_provider>
<persName><json:string>U.S.A. Dosage</json:string>
<json:string>I. Results</json:string>
<json:string>L. Ahmed</json:string>
<json:string>D. A. J. TyrreU</json:string>
</persName>
<placeName></placeName>
<ref_url></ref_url>
<ref_bibl><json:string>Higgins et al. (1983)</json:string>
<json:string>Phillpotts et al., 1984</json:string>
<json:string>see Scott & Tyrrell, 1985</json:string>
<json:string>Merigan et al. (1973)</json:string>
<json:string>Scott et al., 1982b</json:string>
<json:string>Scott et al. (1982a)</json:string>
<json:string>Scott et al., 1982a</json:string>
<json:string>Higgins et al., 1983</json:string>
<json:string>Merigan et al., 1973</json:string>
<json:string>Scott et al. (1982b)</json:string>
</ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/HXZ-1543SRG0-R</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - pharmacology & pharmacy</json:string>
<json:string>2 - microbiology</json:string>
<json:string>2 - infectious diseases</json:string>
</wos>
<scienceMetrix><json:string>1 - health sciences</json:string>
<json:string>2 - biomedical research</json:string>
<json:string>3 - microbiology</json:string>
</scienceMetrix>
<scopus><json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Infectious Diseases</json:string>
<json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Pharmacology (medical)</json:string>
<json:string>1 - Life Sciences</json:string>
<json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string>
<json:string>3 - Pharmacology</json:string>
</scopus>
<inist><json:string>1 - sciences appliquees, technologies et medecines</json:string>
<json:string>2 - sciences biologiques et medicales</json:string>
<json:string>3 - sciences medicales</json:string>
</inist>
</categories>
<publicationDate>1986</publicationDate>
<copyrightDate>1986</copyrightDate>
<doi><json:string>10.1093/jac/18.Supplement_B.153</json:string>
</doi>
<id>0077763261C42E983E3613F4E9CE41A21A08074A</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-1543SRG0-R/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-1543SRG0-R/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/HXZ-1543SRG0-R/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit</title>
<respStmt><resp>Références bibliographiques récupérées via GROBID</resp>
<name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name>
</respStmt>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>Oxford University Press</publisher>
<date when="1986-10">1986</date>
</publicationStmt>
<notesStmt><note type="content-type" source="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note>
<note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit</title>
<author xml:id="author-0000"><persName><surname>Tyrrell</surname>
<forename type="first">D. A. J.</forename>
</persName>
<affiliation><orgName type="institution">MRC Common Cold Unit, Harvard Hospital</orgName>
<address><addrLine>Salisbury Wiltshire, England</addrLine>
</address>
</affiliation>
<affiliation><orgName type="laboratory">MRC Common Cold Unit</orgName>
<orgName type="institution">Harvard Hospital</orgName>
<address><addrLine>Salisbury Wiltshire, England</addrLine>
</address>
</affiliation>
</author>
<idno type="istex">0077763261C42E983E3613F4E9CE41A21A08074A</idno>
<idno type="ark">ark:/67375/HXZ-1543SRG0-R</idno>
<idno type="DOI">10.1093/jac/18.Supplement_B.153</idno>
</analytic>
<monogr><title level="j" type="main">Journal of Antimicrobial Chemotherapy</title>
<title level="j" type="abbrev">J Antimicrob Chemother</title>
<idno type="hwp">jac</idno>
<idno type="publisher-id">jac</idno>
<idno type="pISSN">0305-7453</idno>
<idno type="eISSN">1460-2091</idno>
<imprint><publisher>Oxford University Press</publisher>
<date when="1986-10">1986</date>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">Supplemet_B</biblScope>
<biblScope unit="page" from="153">153</biblScope>
<biblScope unit="page" to="156">156</biblScope>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef>
<appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-09"><label>pub2TEI-ISTEX</label>
<desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
                        <ref target="http://www.tei-c.org/">We use TEI</ref>
</desc>
</application>
</appInfo>
</encodingDesc>
<profileDesc><abstract><p>Intranasal sprays of interferons (IFNs) given one day before and for three days after virus challenge can protect human volunteers from infection with rhinoviruses, corona virus, and influenza. Longer dosage of IFN gives rise to nasal symptoms and signs such as bloodstained nasal discharge. More effective IFNs and regimes are therefore needed. IFNβ is active but the degree to which it will irritate the nose is unknown. Combining IFNs with synthetic antiviral drugs can produce synergistic increases in antiviral activity. It is suggested that these increases may be exploited in future experiments.</p>
</abstract>
<textClass ana="subject"><keywords scheme="heading"><term>Section 3. Strategies for counteraction</term>
</keywords>
</textClass>
<langUsage><language ident="EN"></language>
</langUsage>
</profileDesc>
<revisionDesc><change when="2019-12-09" who="#istex" xml:id="pub2tei">formatting</change>
<change xml:id="refBibs-istex" who="#ISTEX-API" when="2019-12-11">References added</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-1543SRG0-R/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="corpus oup, element #text not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0"</istex:xmlDeclaration>
<istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType>
<istex:document><article article-type="research-article">

<front>

<journal-meta>

<journal-id journal-id-type="hwp">jac</journal-id>

<journal-id journal-id-type="publisher-id">jac</journal-id>

<journal-title>Journal of Antimicrobial Chemotherapy</journal-title>

<abbrev-journal-title>J Antimicrob Chemother</abbrev-journal-title>

<issn pub-type="ppub">0305-7453</issn>

<issn pub-type="epub">1460-2091</issn>

<publisher>

<publisher-name>Oxford University Press</publisher-name>

</publisher>

</journal-meta>

<article-meta>

<article-id pub-id-type="doi">10.1093/jac/18.Supplement_B.153</article-id>

<article-categories>

<subj-group subj-group-type="heading">

<subject>Section 3. Strategies for counteraction</subject>

</subj-group>

</article-categories>

<title-group>

<article-title>The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit</article-title>

</title-group>

<contrib-group>

<contrib contrib-type="author">

<name><surname>Tyrrell</surname>
<given-names>D. A. J.</given-names>
</name>

</contrib>

<aff><institution>MRC Common Cold Unit, Harvard Hospital</institution>
, <addr-line>Salisbury Wiltshire, England</addr-line>
</aff>

</contrib-group>

<pub-date pub-type="ppub">

<month>10</month>

<year>1986</year>

</pub-date>

<volume>18</volume>

<issue>Supplement_B</issue>

<fpage>153</fpage>

<lpage>156</lpage>

<copyright-year>1986</copyright-year>

<abstract>

<p>Intranasal sprays of interferons (IFNs) given one day before and for three days after virus challenge can protect human volunteers from infection with rhinoviruses, corona virus, and influenza. Longer dosage of IFN gives rise to nasal symptoms and signs such as bloodstained nasal discharge. More effective IFNs and regimes are therefore needed. IFNβ is active but the degree to which it will irritate the nose is unknown. Combining IFNs with synthetic antiviral drugs can produce synergistic increases in antiviral activity. It is suggested that these increases may be exploited in future experiments.</p>

</abstract>

</article-meta>

</front>

</article>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo><title>The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA"><title>The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit</title>
</titleInfo>
<name type="personal"><namePart type="given">D. A. J.</namePart>
<namePart type="family">Tyrrell</namePart>
<affiliation>MRC Common Cold Unit, Harvard Hospital, Salisbury Wiltshire, England</affiliation>
</name>
<typeOfResource>text</typeOfResource>
<genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre>
<originInfo><publisher>Oxford University Press</publisher>
<dateIssued encoding="w3cdtf">1986-10</dateIssued>
<copyrightDate encoding="w3cdtf">1986</copyrightDate>
</originInfo>
<abstract>Intranasal sprays of interferons (IFNs) given one day before and for three days after virus challenge can protect human volunteers from infection with rhinoviruses, corona virus, and influenza. Longer dosage of IFN gives rise to nasal symptoms and signs such as bloodstained nasal discharge. More effective IFNs and regimes are therefore needed. IFNβ is active but the degree to which it will irritate the nose is unknown. Combining IFNs with synthetic antiviral drugs can produce synergistic increases in antiviral activity. It is suggested that these increases may be exploited in future experiments.</abstract>
<relatedItem type="host"><titleInfo><title>Journal of Antimicrobial Chemotherapy</title>
</titleInfo>
<titleInfo type="abbreviated"><title>J Antimicrob Chemother</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<identifier type="ISSN">0305-7453</identifier>
<identifier type="eISSN">1460-2091</identifier>
<identifier type="PublisherID">jac</identifier>
<identifier type="PublisherID-hwp">jac</identifier>
<part><date>1986</date>
<detail type="volume"><caption>vol.</caption>
<number>18</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>Supplement-B</number>
</detail>
<extent unit="pages"><start>153</start>
<end>156</end>
</extent>
</part>
</relatedItem>
<identifier type="istex">0077763261C42E983E3613F4E9CE41A21A08074A</identifier>
<identifier type="ark">ark:/67375/HXZ-1543SRG0-R</identifier>
<identifier type="DOI">10.1093/jac/18.Supplement_B.153</identifier>
<accessCondition type="use and reproduction" contentType="copyright">© Oxford University Press. All rights reserved.</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</recordContentSource>
<recordOrigin>Converted from  (version 1.2.0) to MODS version 3.6.</recordOrigin>
<recordCreationDate encoding="w3cdtf">2019-12-09</recordCreationDate>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-1543SRG0-R/record.json</uri>
</json:item>
</metadata>
<covers><json:item><extension>tiff</extension>
<original>true</original>
<mimetype>image/tiff</mimetype>
<uri>https://api.istex.fr/document/0077763261C42E983E3613F4E9CE41A21A08074A/covers/tiff</uri>
</json:item>
</covers>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000164 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000164 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    CovidV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:0077763261C42E983E3613F4E9CE41A21A08074A
   |texte=   The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit
}}

This area was generated with Dilib version V0.6.33.
Data generation: Fri Mar 27 18:14:15 2020. Site generation: Sun Jan 31 15:15:08 2021

	Serveur d'exploration Covid
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Covid

The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit

The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri